Home/Filings/4/0001415889-25-020087
4//SEC Filing

Kintz Samuel 4

Accession 0001415889-25-020087

CIK 0001672619other

Filed

Jul 20, 8:00 PM ET

Accepted

Jul 21, 7:21 PM ET

Size

9.6 KB

Accession

0001415889-25-020087

Insider Transaction Report

Form 4
Period: 2025-07-17
Kintz Samuel
DirectorPRESIDENT AND CEO
Transactions
  • Sale

    Common Stock

    2025-07-17$22.69/sh4,687$106,360944,055 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-07-17$21.58/sh4,150$89,552948,742 total(indirect: See footnote)
  • Sale

    Common Stock

    2025-07-17$23.37/sh3,663$85,607940,392 total(indirect: See footnote)
Footnotes (5)
  • [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
  • [F2]This transaction was executed in multiple trades at prices ranging from $21.26 to $22.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F3]The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
  • [F4]This transaction was executed in multiple trades at prices ranging from $22.28 to $23.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F5]This transaction was executed in multiple trades at prices ranging from $23.285 to $23.595. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Issuer

Enliven Therapeutics, Inc.

CIK 0001672619

Entity typeother

Related Parties

1
  • filerCIK 0001967168

Filing Metadata

Form type
4
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 7:21 PM ET
Size
9.6 KB